[Table_Reportdate] 2025年06月03日 [table_invest] 超配 行 业 周 报 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 赖菲虹 S0630525050001 lfhong@longone.com.cn 联系人 付婷 futing@longone.com.cn [table_stockTrend] -25% -17% -8% 1% 10% 18% 27% 24-05 24-08 24-11 25-02 申万行业指数:医药生物(0737) 沪深300 [相关研究 table_product] 1.重磅BD交易再次带动创新药热度 — — — — 医 药 生 物 行 业 周 报 （2025/05/19-2025/05/25） [Table_NewTitle 创新药密集上市， ] 关注后续医保谈判 ————医药生物行业周报（2025/05/26-2025/06/01） [table_main] 投资要点： ➢ 市场表现： 上周（05月26日-05月30日）医药生物板块整体上涨2.21%，在申万31个行业中排第 2位，跑赢沪深300指数3. ...

2. 石药集团(01093.HK)：正与潜在交易方进行磋商，涉及有关药品开发、生产及商业化方面的授权及合 作。 3. 三一国际(00631.HK)：一季度溢利净额同比增长30.6%达6.36亿元 大港机、油气装备、硅能产品收入 及矿车海外收入大幅增加。 4. 闽信集团(00222.HK)：联合成立合伙企业，参投国家级专精特新科技企业。 金十数据整理：每日港股市场要闻速递（5月30日 周五） 个股新闻 1. 理想汽车(02015.HK) ：2025年Q1收入总额为259亿元，同比增长1.1%；经调整净利润为10亿元，同比 下滑20.5%。 5. 中国东方集团(00581.HK)：一季度扣除财务成本净额后的经营溢利约1.99亿元。 8. 嘉和生物(06998.HK)：中国药监局批准来罗西利(GB491)新药上市申请。 6. 复星医药(02196.HK)：芦沃美替尼片的上市注册申请获国家药监局批准。 7. 百胜中国(09987.HK)：订立下半年总回购金额约5.1亿美元的股份回购协议。 ...

Group 1: Stablecoin Legislation in Hong Kong - The Hong Kong Legislative Council passed the "Stablecoin Ordinance" on May 21, marking Hong Kong as one of the first regions globally to establish a comprehensive regulatory framework for fiat-backed stablecoins [1] - The Hong Kong Monetary Authority (HKMA) will initiate a licensing system to regulate stablecoin issuance and related activities, with compliance applications expected to be accepted by the end of 2025 [1] - Stablecoins are seen as a means to promote the internationalization of the Hong Kong dollar and the Renminbi, challenge the dominance of the US dollar in the digital currency era, and enhance the cross-border payment environment [1] Group 2: Investment Opportunities and Benefits - Issuers of stablecoins can gain commercial benefits such as minting profits, increasing user engagement within their ecosystems, and expanding customer reach, particularly among unbanked populations [1] - Investors can benefit from stablecoins by avoiding cryptocurrency volatility, meeting cross-border payment needs, participating in DeFi investments, and managing liquidity [1] - Licensed institutions are expected to generate revenue through a combination of interest spreads, fees, and ecosystem services [1] Group 3: Company Announcements and Financial Performance - China Eastern Group reported a sales volume of approximately 1.8 million tons of self-produced steel products for the first quarter, with a gross profit of about 100-150 RMB per ton [9] - Shenzhen Expressway reported a revenue of 97.14 million RMB for its outer ring project in April, reflecting a year-on-year decrease of approximately 9.21% [10] - Sany International reported a revenue of 5.876 billion RMB for the first quarter, a year-on-year increase of 14.6%, with a net profit attributable to shareholders of 635 million RMB, up 23.2% [17]

智通财经APP获悉，据港交所4月15日披露，嘉和生物-B(06998)向港交所递交上市申请书。亿腾医药通过换股方式反向收购嘉和生物，合并后公司更名为"亿 腾嘉和医药集团有限公司"。摩根士丹利和浦银国际为新上市申请联席保荐人。 | 治療領域 | 候還產品 | 檀應症 | 作用機制 | 分類 | 來源 | 搜量 | 產品權利 | IND | I/II期 | 川期 | 新疆 新疆 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 原研產品 | | | | | | | | | | | | | 抗感染 | 穩可信 | JIRSA | 糖肽 | 原研樂 | 收購藥品 | 禮來 | 中國、意大利 | | | | | | | 希刻勞 | 草蘭氏 陽性／陰性 頭孢菌素 細菌感染! | | | 原研藥 收購藥品 | 禮來 | 中國 | | | | | | 呼吸系統 | 億瑞平 | 哮喘 | ICS | | 原研藥 收購藥品 | GSK | 中國、荷蘭 | | | | | | 創新產品 | | | | | | | | | | ...